Meals and Medication Administration , placing the Swiss drugmaker before rivals focusing on similar tumor therapies. Document PHOTO: The logo design of Swiss drugmaker Novartis AG sometimes appears at its head office in Basel, Switzerland, 25 january, 2017. The medicine, called CTL019, is cure for young patients with B-cell severe lymphoblastic leukemia. On Thursday night novartis stocks were little changed, but UK-based Oxford BioMedica, making elements for CTL019 and can reap undisclosed royalties from potential sales, rose a lot more than 4.5 % within the announcement. Basel-based Novartis is currently in pole position with regulators since it pushes for approval alongside rivals including biotech Kite Pharma Inc that are growing similar therapies. CTL019 will probably cost thousands of dollars per patient if approved, and Novartis counts it among medicines it believes will eventually exceed $1 billion in annual sales.A low-threshold activation of Fas, nevertheless, can cause cell duplication or an inflammatory response without cell loss of life occurring. Insufficient Fas receptor protects against a fatty liver In our research, we could actually demonstrate in mouse choices that Fas is activated inside the range of obesity and may therefore result in the introduction of liver organ steatosis, says Prof. Dr. Med. Daniel Konrad, teacher for endocrinology and diabetology from your University or college of Zurich and doctor on the School Children’s Medical center Zurich. Mice lacking Fas within their liver organ cells were safeguarded against the introduction of obesity-induced fatty liver organ generally.